Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Assessment of Diaphragmatic Function After Stellate Ganglion Block

22. juli 2026 opdateret af: Jose Manuel López González

Diaphragmatic Ultrasound and Spirometry After Ultrasound-guided Stellate Ganglion Block: a Prospective Observational Study

The objective of our study was to evaluate the incidence of hemidiaphragmatic paralysis after ultrasound-guided stellate ganglion block (US-SGB) by assessing diaphragmatic excursion and diaphragmatic thickening fraction using diaphragm ultrasound.

Studieoversigt

Detaljeret beskrivelse

A prospective, single-center observational study was designed with the aim of evaluating diaphragmatic excursion and diaphragmatic thickening fraction, measured by ultrasound before and 30 minutes after US-SGB performed with 10 mL of 0.25% levobupivacaíne.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

15

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Principality of Asturias
      • Oviedo, Principality of Asturias, Spanien, 33001
        • FINBA

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

After approval of the study by the Principality of Asturias Drug Research Ethics Committee (CEImPA), Spain, and obtaining informed consent from the participants, all consecutive patients undergoing a first diagnostic US-SGB for sympathetic nervous system-mediated disorders were prospectively included.

Beskrivelse

Inclusion Criteria:

  • patients over 18 years of age.
  • patients with sympathetic nervous system-mediated disorders.

Exclusion Criteria:

  • patients younger than 18 years of age.
  • patients with severe chronic obstructive pulmonary disease.
  • previous diaphragmatic paralysis or neuromuscular disease.
  • inability to undergo diaphragmatic ultrasound.
  • patients with neck anatomy considered unsuitable for the procedure (including previous neck surgery, burns, extensive scarring or large goiters resulting in distortion of normal cervical anatomy).
  • contraindications to the interventional technique (such as infection at the puncture site, or refusal to provide consent).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
US-SGB
Patients with sympathetic nervous system-mediated disorders of the upper limb undergoing a first diagnostic ultrasound-guided stellate ganglion block (US-SGB).
US-SGB was performed at the C7 level using 10 ml of 0.25% levobupivacaíne.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Diaphragmatic excursion
Tidsramme: The diaphragmatic excursion, assessed by diaphragm ultrasound before and 30 minutes after US-SGB.
Excursion of the diaphragmatic dome was assessed by a pulmonologist experienced in diaphragm ultrasound assessment. Once the dome was identified, excursion was measured in M-mode as the distance, in centimeters, between the end-expiratory and end-inspiratory positions during a vital capacity manoeuvre.
The diaphragmatic excursion, assessed by diaphragm ultrasound before and 30 minutes after US-SGB.
Diaphragmatic thickening fraction
Tidsramme: The diaphragmatic thickening, assessed by diaphragm ultrasound before and 30 minutes after US-SGB.

The diaphragmatic thickening fraction was assessed by a pulmonologist experienced in diaphragm ultrasound assessment. Diaphragm thickness was measured, in centimeters, at end-inspiration and end-expiration during a vital capacity manoeuvre. Thickening fraction was calculated using the following formula and expressed as a percentaje:

Thickening fraction = [(thickness at end-inspiration - thickness at end-expiration) / thickness at end-expiration] x 100.

The diaphragmatic thickening, assessed by diaphragm ultrasound before and 30 minutes after US-SGB.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Forced vital capacity (FVC)
Tidsramme: Spirometric parameters measured at baseline and 1 hour after US-SGB.
Measure of the maximum exhaled volume of air (in liters, L) after a deep breath, on spirometry performed using a pneumotachograph spirometer.
Spirometric parameters measured at baseline and 1 hour after US-SGB.
Forced expiratory volume in 1 second (FEV1)
Tidsramme: Spirometric parameters measured at baseline and 1 hour after US-SGB.
Measure of the exhaled air volume (in liters, L) in the first second of the spirometry, performed using a pneumotachograph spirometer
Spirometric parameters measured at baseline and 1 hour after US-SGB.
Tiffeneau index (FEV1/FVC ratio)
Tidsramme: Spirometric parameters measured at baseline and 1 hour after US-SGB.
Ratio between the aforementioned FEV1 and FVC expressed in percentage (%), derived from the parameters obtained on spirometry.
Spirometric parameters measured at baseline and 1 hour after US-SGB.
Peripheral oxygen saturation (SpO2)
Tidsramme: Measured at baseline and 1 hour after US-SGB.
Peripheral blood oxygen saturation (SpO2) expressed in percentage (%), measured using a digital pulse oximeter.
Measured at baseline and 1 hour after US-SGB.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Daniel García Iglesias, MD, PhD, Central University Hospital of Asturias, 33001, Spain

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. december 2024

Primær færdiggørelse (Faktiske)

10. december 2025

Studieafslutning (Faktiske)

1. juni 2026

Datoer for studieregistrering

Først indsendt

15. juli 2026

Først indsendt, der opfyldte QC-kriterier

22. juli 2026

Først opslået (Faktiske)

23. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Stellat ganglieblok

Kliniske forsøg med Ultrasound-guided stellate ganglion block

Abonner